Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rumiko Shimazawa

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Health Security|March 28, 2015
Development of drug-approval regulations for medical countermeasures against CBRN agents in JapanRumiko Shimazawa, Masayuki Ikeda
Journal of Pharmaceutical Policy and Practice|December 14, 2019
Imbalance in glycemic control between the treatment and placebo groups in cardiovascular outcome trials in type 2 diabetesRumiko Shimazawa, Masayuki Ikeda
British Journal of Clinical Pharmacology|May 29, 2025
Consideration of ethnic differences in approvals for anti-HIV medicines in Japan: Evaluation based on pharmacokinetic studies and post-marketing dataRumiko Shimazawa, Masayuki Ikeda
Expert Review of Molecular Diagnostics|December 15, 2015
Drug-diagnostic co-development: challenges and issuesRumiko Shimazawa, Masayuki Ikeda
Journal of General and Family Medicine|July 18, 2019
Challenges to hemoglobin A1c as a therapeutic target for type 2 diabetes mellitusMasayuki Ikeda, Rumiko Shimazawa
Psychiatry and Clinical Neurosciences|May 8, 2014
Conflicts of interest in psychiatry: strategies to cultivate literacy in daily practiceRumiko Shimazawa, Masayuki Ikeda
Expert Review of Molecular Diagnostics|October 14, 2014
International differences in companion diagnostic approvals: how are we able to manage the differences?Rumiko Shimazawa, Masayuki Ikeda
Pharmacology Research & Perspectives|May 11, 2026
An Evaluation of Foreign Clinical Data in the Approval Reviews of Antimicrobial Medicines in Japan: Considering Ethnic and Regional Differences in Data Extrapolations in Accordance With Regulatory CircumstancesRumiko Shimazawa, Masayuki Ikeda
Internal Medicine (Tokyo, Japan)|August 2, 2011
Delays in neurological drug development in JapanRumiko Shimazawa, Masayuki Ikeda
Journal of Pharmaceutical Policy and Practice|January 11, 2017
Approval status and evidence for WHO essential medicines for children in the United States, United Kingdom, and Japan: a cross-sectional studyRumiko Shimazawa, Masayuki Ikeda
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Health Security|March 28, 2015
Development of drug-approval regulations for medical countermeasures against CBRN agents in JapanRumiko Shimazawa, Masayuki Ikeda
Journal of Pharmaceutical Policy and Practice|December 14, 2019
Imbalance in glycemic control between the treatment and placebo groups in cardiovascular outcome trials in type 2 diabetesRumiko Shimazawa, Masayuki Ikeda
British Journal of Clinical Pharmacology|May 29, 2025
Consideration of ethnic differences in approvals for anti-HIV medicines in Japan: Evaluation based on pharmacokinetic studies and post-marketing dataRumiko Shimazawa, Masayuki Ikeda
Expert Review of Molecular Diagnostics|December 15, 2015
Drug-diagnostic co-development: challenges and issuesRumiko Shimazawa, Masayuki Ikeda
Journal of General and Family Medicine|July 18, 2019
Challenges to hemoglobin A1c as a therapeutic target for type 2 diabetes mellitusMasayuki Ikeda, Rumiko Shimazawa
Psychiatry and Clinical Neurosciences|May 8, 2014
Conflicts of interest in psychiatry: strategies to cultivate literacy in daily practiceRumiko Shimazawa, Masayuki Ikeda
Expert Review of Molecular Diagnostics|October 14, 2014
International differences in companion diagnostic approvals: how are we able to manage the differences?Rumiko Shimazawa, Masayuki Ikeda
Pharmacology Research & Perspectives|May 11, 2026
An Evaluation of Foreign Clinical Data in the Approval Reviews of Antimicrobial Medicines in Japan: Considering Ethnic and Regional Differences in Data Extrapolations in Accordance With Regulatory CircumstancesRumiko Shimazawa, Masayuki Ikeda
Internal Medicine (Tokyo, Japan)|August 2, 2011
Delays in neurological drug development in JapanRumiko Shimazawa, Masayuki Ikeda
Journal of Pharmaceutical Policy and Practice|January 11, 2017
Approval status and evidence for WHO essential medicines for children in the United States, United Kingdom, and Japan: a cross-sectional studyRumiko Shimazawa, Masayuki Ikeda
Pageof 4